OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
We have used patient-specific stem cell technology to uncover a surprising interplay between gain- and loss-of-function disease mechanisms in the most common form of ALS and FTD, caused by a repeat expansion mutation in C9ORF72. In addition, we have used high-throughput chemical screens on patient-derived neurons to identify novel therapeutic targets for C9ORF72 and sporadic ALS. Recently, we have developed a systematic approach for the identification of gene variants that cause sporadic ALS and are using it to investigate potential new ALS genes with key roles in proteostasis.
